Cellectis Allogeneic Car-T Cells

Cellectis Allogeneic CAR-T Cells

Cellectis' gene edited CAR T-cells: how does it work?

Allogeneic CAR-T cells: for hematological malignancies and solid tumors ?

In the Stem Cell Jungle

UCARTCS1: a novel allogeneic CAR-T therapy for myeloma

VJHemOnc – Video Journal of Hematology & HemOnc

Cellectis 2020 shareholders video

Cellectis Innovation Days - Episode 2

Cellectis Innovation Days- Episode 1

Lecture: Creating A Universal Donor-Derived Cell Therapy, Thierry Wurch

An insight into CTX130: a novel allogeneic CAR-T cell therapy

VJHemOnc – Video Journal of Hematology & HemOnc

Science in the Age of Experience 2024 - David Sourdive, Cellectis

Dassault Systèmes

Allogeneic CAR T-Cell Approaches for NHL

What is an allogeneic CAR-T cell? #myeloma

HealthTree University for Multiple Myeloma

Moffitt Medical Minute (Ep. 34) - Autologous vs. Allogenic CAR T

Moffitt Cancer Center

Using TALEN gene editing to improve the efficacy of T-cell therapies

VJHemOnc – Video Journal of Hematology & HemOnc

Complete CAR T Manufacturing Control with Cellectis' Steve Doares

Life Science Connect

The current landscape of allogeneic CAR T-cell therapies

Novel allo-CART therapies and their role in the treatment of hematological malignancies

VJHemOnc – Video Journal of Hematology & HemOnc

Azer-cel best in class Allogeneic CAR T cell therapy?

Imugene Limited

Biotech Drop Does Not Dim Immunotherapy Progress Says Cellectis CEO

Advances in allogeneic CAR-T therapy in lymphoma

VJHemOnc – Video Journal of Hematology & HemOnc